Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

Peyronie's disease affects about 6% of middle-aged ... Pentoxifylline is a nonselective phosphodiesterase inhibitor thought to have anti-inflammatory and antifibrogenic activity.

A new study published in the CHEST journal found that ensifentrine, an innovative inhaled therapy, significantly reduces the ...

As Healio previously reported, a 12-week phase 2 trial found that treatment with an 18 mg dose of the phosphodiesterase ... in the research of this disease, and we look forward to sharing full ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been ... preferential inhibitor of phosphodiesterase 4B (PDE4B). The therapy was granted FDA Breakthrough Therapy Designation for ...

Specialty pharmacy expands access to an innovative, steroid-free treatment NEW PROVIDENCE, NJ, UNITED STATES, March 3, 2025 /EINPresswire / -- ...

Detailed price information for Verona Pharma Plc ADR (VRNA-Q) from The Globe and Mail including charting and trades.